The Gabriel Rosenberg Dyspraxia/Developmental Coordination Disorder (DCD) Coverage Act requires the Comptroller General (GAO) to produce a report within one year assessing how items and services for dyspraxia/DCD are covered across Medicare, each State’s Medicaid program, other federal health programs, group and individual private plans, and the Federal Employees Health Benefits (FEHB) program. The study lists specific lines of inquiry: whether coverage exists, what services are covered, any age-based cutoffs, barriers to coverage, and whether plans comply with statutory coverage rules (PHSA §2726 as cited).
This is a data-gathering bill rather than a coverage mandate. The results could trigger administrative guidance from CMS, state policy changes, insurer plan design adjustments, or legislative follow-ups — making the GAO’s methodology, data sources, and recommendations consequential for payers, clinicians, and families managing DCD care needs.
At a Glance
What It Does
Directs the Comptroller General to conduct and deliver, within one year of enactment, a study and report on coverage of items and services for dyspraxia/DCD across Medicare, state Medicaid programs, other federal health programs, group and individual private plans, and the FEHB program. The statute enumerates eleven discrete topics the GAO must address, including types of covered services, age cutoffs, barriers to coverage, and recommendations for CMS guidance.
Who It Affects
GAO will perform the study; CMS, state Medicaid agencies, Federal health program managers, ERISA plan sponsors and insurers, and the FEHB administrator will be key data sources and potential audiences. Clinicians (occupational/physical therapists, pediatricians), patient advocacy groups, and families living with DCD are downstream stakeholders likely to act on the report’s findings.
Why It Matters
The bill creates an evidentiary baseline on payer practices for DCD treatment that currently lacks a unified federal inventory. That baseline can shape regulatory guidance, inform state coverage mandates, prompt insurer policy changes, or underpin future legislation — so the study’s scope and recommendations matter more than the bill’s immediate legal force.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The Act is short and specific: it orders the Comptroller General to study how payers treat items and services related to dyspraxia/DCD and to report back to Congress within a year. The law identifies the payers and programs to be reviewed — Medicare, each State’s Medicaid program, other federal health programs as defined in the Social Security Act, group and individual private health plans, and the program under chapter 89 of title 5 (FEHB) — and supplies a checklist of eleven topics the GAO must answer.
Those topics are practical rather than theoretical. The GAO must determine whether coverage exists in each program, catalog the kinds of services that are covered when coverage is available, and identify any age-based cutoffs that lead to loss of coverage when a child becomes an adult.
The study must also probe barriers—explicit (plan exclusions) and implicit (lack of qualified providers)—and whether private plans conform with the cited Public Health Service Act requirement (section 2726).Because the statute does not itself change benefits, the value of the bill will rest on the GAO’s data collection and recommendations. To be useful, GAO will need to combine administrative claims data, plan benefit documents, state Medicaid policy reviews, and interviews or surveys of payers and provider groups.
The statute explicitly asks for recommendations on whether CMS should issue guidance and on ways private plans could improve coverage, thereby positioning the report as a potential catalyst for agency action or legislative fixes.Practically, the study will illuminate common coverage patterns (for example, which therapies are reimbursed, whether durable medical equipment is covered, and how states differ), expose administrative and provider-side bottlenecks, and clarify whether diagnostic transitions between childhood and adulthood create coverage gaps. Those findings will feed regulators, state policymakers, insurers, clinicians, and advocacy organizations seeking better access or clearer rules for DCD treatment.
The Five Things You Need to Know
The GAO must deliver the study and report to Congress not later than one year after the Act’s enactment.
The study must examine coverage under Medicare, each State’s Medicaid program, other federal health programs, group and individual private plans, and the Federal Employees Health Benefits (FEHB) program (chapter 89, title 5).
GAO’s report must identify the types of items and services generally covered when coverage exists, and catalog any age cutoffs that cause beneficiaries to lose coverage when they age out of pediatric eligibility.
The statute requires GAO to assess barriers to coverage (including provider shortages) and whether group and individual plans comply with the requirements of section 2726 of the Public Health Service Act.
The Act explicitly asks GAO to recommend whether the Centers for Medicare & Medicaid Services should issue guidance on DCD coverage and to offer recommendations for improving coverage by private plans.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title
Designates the bill as the 'Gabriel Rosenberg Dyspraxia/DCD Coverage Act.' This is purely nominal but signals the bill's targeted policy focus on dyspraxia/DCD and identifies the report as the named Act's deliverable.
GAO study and report mandate
Directs the Comptroller General to conduct a study and submit a report to Congress within one year of enactment. The clause fixes the timeline and the responsible federal actor (GAO), which frames the remainder of the section as a required data-gathering exercise rather than a directive to agencies or insurers to change benefits.
Required study elements and scope
Lists the eleven discrete inquiries GAO must address: whether Medicare covers DCD-related items and services; state-by-state Medicaid coverage; coverage under other federal health programs; extent of coverage under group and individual plans; types of covered services; age cutoffs; barriers to coverage (e.g., provider shortages); compliance with PHSA §2726; whether diagnostic criteria change at adulthood causing coverage loss; and recommendations on CMS guidance and private plan improvements. Each enumeration sets a clear reporting obligation and narrows GAO’s research questions, which also signals likely data sources: Medicare/Medicaid claims, state plan documents, insurer benefit summaries, and stakeholder interviews.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Families and individuals with DCD — a comprehensive GAO inventory can clarify whether existing coverage gaps are administrative (missing provider networks) or policy-driven, supporting advocacy for better access or targeted fixes.
- Pediatric and rehabilitation clinicians (occupational/physical therapists) — the study may spotlight unmet demand and could justify reimbursement negotiations, network-building, or training investments.
- State Medicaid agencies and CMS — the report provides a consolidated evidence base to compare coverage approaches across states and programs, helping officials design more consistent policies or guidance.
- Patient advocacy groups focused on neurodevelopmental conditions — the findings give these groups data-backed leverage for policy campaigns and public education.
Who Bears the Cost
- Insurers and ERISA plan sponsors — while the bill does not force benefit changes, GAO recommendations and subsequent CMS guidance or state action could lead insurers to expand covered services or face regulatory scrutiny, imposing actuarial and administrative costs.
- State governments — if the report prompts state-level mandates or Medicaid benefit expansions, states may face budgetary pressures to add services or increase provider payments.
- Federal health program administrators (CMS, FEHB managers) — responding to GAO findings could require rulemaking, guidance development, beneficiary outreach, or systems changes, all of which incur time and resources.
- Small provider practices — if the report increases demand for DCD services, small practices may need to invest in training, billing capabilities, or expansion, and they may face initial reimbursement uncertainty.
Key Issues
The Core Tension
The central dilemma is between building a robust, evidence-based picture of coverage (which requires broad, comparable data and can reveal unmet need) and the political and fiscal consequences of acting on that picture: clearer coverage can improve access for people with DCD but also pressures payers and governments to expand benefits and funding, a trade-off with no simple technical fix.
The bill is a study directive, not a coverage mandate, which creates two linked implementation challenges. First, the GAO’s usefulness will hinge on access to comparable data across private plans, state Medicaid programs, and federal programs; differences in coding practices, benefit document terminology, and claims visibility will complicate apples-to-apples comparisons.
GAO will likely encounter limits in private-plan claims access and in heterogenous Medicaid policies (state plan provisions, waivers, managed care contracts), making definitive prevalence estimates difficult.
Second, several of the statutory prompts presuppose clear clinical and administrative boundaries that may not exist in practice. For example, asking whether children 'fail to meet the diagnosis criteria' as adults raises clinical, diagnostic, and policy questions about how DCD is defined across age spans and who makes that determination for coverage purposes.
Similarly, citing compliance with PHSA §2726 imports an existing statutory standard without clarifying how that standard has been applied to neurodevelopmental motor disorders historically. Those ambiguities could produce recommendations that are precise on paper but hard to operationalize without additional clinical consensus or rulemaking.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.